Trial · NCT00859937

Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

NCT00859937, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2015-04-03

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors. Trials, record NCT00859937. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00859937

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
NCT number: NCT00859937
Status: Completed
Phases: Phase 2
Enrollment: 55 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Malignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v7
Interventions: Dasatinib, Laboratory Biomarker Analysis
First posted: 2009-03-11
Last updated: 2018-04-20
Results first posted: 2015-04-03

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Response Rate	Up to 2 months	Response rate is percentage of the best overall response which recoded from the start of the treatment until diseases progression/recurrence. Response criteria are defined using the international criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) Committee: Complete Response, Disappearance of all target lesions; Partial Response, \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease, neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.
Primary	Progression-free Survival	up to 5 years	Progression-free survival from start of treatment to the time of disease progression or death from any cause was estimated using the Kaplan-Meier method.
Secondary	Overall Survival	Up to 5 years	Kaplan-Meier curves will be generated and 90% confidence intervals will be derived.
Secondary	Changes in Laboratory Correlates	Baseline and 4 weeks	Changes in laboratory correlates pre-post therapy will be analyzed using paired t-tests. The association between RET gene rearrangements/mutations and tumor response, as well as the association between germ-line polymorp response, will be analyzed using Fisher's exact test. The correlative and genetic data will also be entered as cova only due to the small sample size) in a Cox regression model of progression-free survival.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Response Rate	Up to 2 months	There are two subtype cohorts, adenoid cystic carcinoma and non adenoid cystic carcinoma of malignant salivary gland tumors, with the same treatment. The two groups were analyzed separately and therefore no comparisons are made between the two groups.	participants	NUMBER
PRIMARY	Progression-free Survival	up to 5 years	There are two subtype cohorts, adenoid cystic carcinoma and non adenoid cystic carcinoma of malignant salivary gland tumors, with the same treatment. The two groups were analyzed separately and therefore no comparisons are made between the two groups.	months	MEDIAN
SECONDARY	Overall Survival	Up to 5 years	There are two subtype cohorts, adenoid cystic carcinoma and non adenoid cystic carcinoma of malignant salivary gland tumors, with the same treatment. The two groups were analyzed separately and therefore no comparisons are made between the two groups.	months	MEDIAN
SECONDARY	Changes in Laboratory Correlates	Baseline and 4 weeks	Biomarkers not done due to insufficient clinical responses thus making the biomarker analysis scientifically untenable.

Source ClinicalTrials.gov

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Response Rate	Adenoid Cystic Carcinoma	Complete response	0	participants
Response Rate	Non Adenoid Cystic Carcinoma	Complete response	0	participants
Response Rate	Adenoid Cystic Carcinoma	Partial response	1	participants
Response Rate	Non Adenoid Cystic Carcinoma	Partial response	0	participants
Response Rate	Adenoid Cystic Carcinoma	Stable disease	20	participants
Response Rate	Non Adenoid Cystic Carcinoma	Stable disease	7	participants
Response Rate	Adenoid Cystic Carcinoma	Progressive disease	12	participants
Response Rate	Non Adenoid Cystic Carcinoma	Progressive disease	4	participants
Response Rate	Adenoid Cystic Carcinoma	Other	7	participants
Response Rate	Non Adenoid Cystic Carcinoma	Other	3	participants

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Adenoid Cystic Carcinoma	41
Overall Study	STARTED	Non Adenoid Cystic Carcinoma	14
Overall Study	COMPLETED	Adenoid Cystic Carcinoma	40
Overall Study	COMPLETED	Non Adenoid Cystic Carcinoma	14
Overall Study	NOT COMPLETED	Adenoid Cystic Carcinoma	1
Overall Study	NOT COMPLETED	Non Adenoid Cystic Carcinoma	0

Source ClinicalTrials.gov

Adverse events206

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Abdominal distension	Gastrointestinal disorders	Adenoid Cystic Carcinoma	0	40
other	Abdominal distension	Gastrointestinal disorders	Non Adenoid Cystic Carcinoma	1	14
other	Activated partial thromboplastin time prolonged	Investigations	Adenoid Cystic Carcinoma	0	40
other	Activated partial thromboplastin time prolonged	Investigations	Non Adenoid Cystic Carcinoma	1	14
other	Alanine aminotransferase increased	Investigations	Adenoid Cystic Carcinoma	10	40
other	Alanine aminotransferase increased	Investigations	Non Adenoid Cystic Carcinoma	4	14
other	Alkaline phosphatase increased	Investigations	Adenoid Cystic Carcinoma	7	40
other	Alkaline phosphatase increased	Investigations	Non Adenoid Cystic Carcinoma	0	14
other	Allergic reaction	Immune system disorders	Adenoid Cystic Carcinoma	2	40
other	Allergic reaction	Immune system disorders	Non Adenoid Cystic Carcinoma	0	14

1 to 10 of 206Source ClinicalTrials.gov

See all 206 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Adenoid Cystic Carcinoma
Total, all-cause mortality	Non Adenoid Cystic Carcinoma
Total, other adverse events	Adenoid Cystic Carcinoma	39	40
Total, other adverse events	Non Adenoid Cystic Carcinoma	13	14
Total, serious adverse events	Adenoid Cystic Carcinoma	12	40
Total, serious adverse events	Non Adenoid Cystic Carcinoma	8	14

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P30CA014599	Cancer Center Support Grant	ODUNSI, KUNLE	UNIVERSITY OF CHICAGO	NATIONAL CANCER INSTITUTE	1985 to 2025

Source NIH RePORTER

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Adenoid Cystic Carcinoma vs Non Adenoid Cystic Carcinoma: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00859937

GET https://conductscience.org/api/trials/v1/NCT00859937/events?page=2

API reference For AI assistants